Market Place
Sourcing Support
Psyence Group Closes Sale of Stake in PsyLabs
31 Oct 2024 //
GLOBENEWSWIRE
Psyence Biomedical Closes Acquisition of PsyLabs Stake
31 Oct 2024 //
GLOBENEWSWIRE
Psyence Biomedical Recruits Second Site for Psilocybin Trial
25 Oct 2024 //
GLOBENEWSWIRE
Psyence Group Enters Debt-For-Equity Swap With Psyence Biomedical
14 Oct 2024 //
GLOBENEWSWIRE
Psyence walks away from acquisition of fellow psilocybin biotech
07 Oct 2024 //
FIERCE BIOTECH
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
20 Sep 2024 //
GLOBENEWSWIRE
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
19 Sep 2024 //
GLOBENEWSWIRE
Psyence Biomed Issues Progress And Milestones Update
18 Sep 2024 //
GLOBENEWSWIRE
Psyence Biomed Issues Update On Progress And Milestones
16 Sep 2024 //
GLOBENEWSWIRE
Psyence Biomedical Initiates Australian Trial Site
16 Sep 2024 //
GLOBENEWSWIRE
Psyence Biomedical Receives Nasdaq Delisting Determination
13 Sep 2024 //
GLOBENEWSWIRE
Psyence Biomed Initiates First Trial Site In Australia
09 Sep 2024 //
GLOBENEWSWIRE
Psyence Biomed Licenses PsyLabs` Nature-Derived Psilocybin
04 Sep 2024 //
GLOBENEWSWIRE
Psyence Biomed Announces SEC Approval For $25M Equity Line Of Credit
30 Aug 2024 //
GLOBENEWSWIRE
Optimi Health And Psyence Biomedical Sign LOI For Psilocybin Development
13 Aug 2024 //
GLOBENEWSWIRE
Psyence Biomed Enters $25M Stock Purchase Agreement With White Lion
31 Jul 2024 //
GLOBENEWSWIRE
Psyence Biomedical Exports Psilocybin To Australia, Updates On Phase IIb Trial
26 Jul 2024 //
GLOBENEWSWIRE
Psyence Biomed Exports Psilocybin To Australia, Updates On Phase IIb Trial
24 Jul 2024 //
GLOBENEWSWIRE
Psyence Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
03 Jul 2024 //
GLOBENEWSWIRE
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
17 May 2024 //
GLOBENEWSWIRE
Psyence Biomedical Partners with Fluence
16 Apr 2024 //
GLOBENEWSWIRE
Psyence Welcomes Results of Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
18 Mar 2024 //
GLOBENEWSWIRE
Psyence Receives Nasdaq Notifications Regarding Market Value of Securities
15 Mar 2024 //
GLOBENEWSWIRE
Psyence Issues Shareholder Letter Recapping Recent Progress
12 Mar 2024 //
GLOBENEWSWIRE
Psyence Biomedical, Receives Approval to Initiate Phase IIb Study
12 Mar 2024 //
GLOBENEWSWIRE
Psyence Biomedical Ltd. Approved to List on Nasdaq
25 Jan 2024 //
GLOBENEWSWIRE
Psyence announces signing of definitive agreement for a convertible note
16 Jan 2024 //
GLOBENEWSWIRE
Psyence Production Expands Capability
30 Oct 2023 //
GLOBENEWSWIRE
Psyence Announces Closing of Private Placement & Conclusion of Loan Agreement
21 Aug 2023 //
GLOBENEWSWIRE
Psyence Group Announces SEC Registration Filing with NASDAQ SPAC
02 Aug 2023 //
GLOBENEWSWIRE
Psyence Group Corporate Update
12 Jul 2023 //
GLOBENEWSWIRE
Psyence Appoints Intellectual Property Expert to Its Board of Directors
11 Jul 2023 //
GLOBENEWSWIRE
Psyence Group Announces Closing of Fourth Tranche of Private Placement
03 Apr 2023 //
GLOBENEWSWIRE
Psyence Group Announces Cantheon Capital Private Placement
23 Mar 2023 //
GLOBENEWSWIRE
Psyence Partners with iNGENÅ« for Palliative Care Clinical Trial in Australia
21 Mar 2023 //
GLOBENEWSWIRE
Psyence and Eden Labs Announce Extraction and Product Development Collaboration
24 Jan 2023 //
GLOBENEWSWIRE
Psyence Group Completes Export of Pharma Grade Psilocybin Extract to UK
20 Jan 2023 //
GLOBENEWSWIRE
Psyence Announces Combination between Psyence & Newcourt Acquisition Corp
09 Jan 2023 //
GLOBENEWSWIRE
Psyence Signs Letter of Intent with Australian CRO iNGENÅ«
08 Jan 2023 //
GLOBENEWSWIRE
Psyence and Filament Announce Licensing Agreement of Psilocybin Capsule
15 Dec 2022 //
GLOBENEWSWIRE
Psyence Group Announces Closing of Second Tranche of Private Placement
14 Dec 2022 //
GLOBENEWSWIRE
Canadian and US developers to trial psychedelic medicines in UK
13 Dec 2022 //
EUROPEANPHARMACEUTICALREVIEW
GOODMIND Available for Sale in the United Kingdom and Europe
29 Nov 2022 //
GLOBENEWSWIRE
Psyence Group Completes Export of Psilocybin Mushrooms to Portugal
29 Sep 2022 //
GLOBENEWSWIRE
Psyence Group Completes Export of Psilocybin Mushrooms to Canada
22 Sep 2022 //
GLOBENEWSWIRE
UK MHRA grants approval for Psyence’s Phase IIa adjustment disorder trial
20 Sep 2022 //
CLINICALTRIALS ARENA
Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines
19 Sep 2022 //
GLOBENEWSWIRE
Psyence Group Corporate Update
02 Jun 2022 //
GLOBENEWSWIRE
Psyence Taps Another Pharma Exec to Drive its Clinical Program
31 May 2022 //
GLOBENEWSWIRE
Psyence and Filament Health Enter Into Exclusive Licensing Agreement
19 Apr 2022 //
GLOBENEWSWIRE
Psyence Group Functional Mushroom Brand “GOODMIND™” Commences
02 Dec 2021 //
GLOBENEWSWIRE
Psyence Group Invited as First Psychedelic Company to present at the 15th
26 Nov 2021 //
GLOBENEWSWIRE
Psyence Group Announces Commencement of Trading on OTCQB and DTC
13 Oct 2021 //
GLOBENEWSWIRE
